Oramed Pharma ORMP

$3.71 -0.32 (-7.94%)

Valuation

Market cap
154,325,000
Revenue TTM
$2,000,000
Net income TTM
$64,050,000
P/E (trailing)
0.00
P/E (forward)
2.74
Profit margin
3,202.50%
Debt to equity
0.00

Trading

Volume
161,300
Avg volume
148,178
Day's range
$3.67 – $4.12
Shares out
41,597,000
Stochastic %K
7%
Beta
1.31
Analysts
Hold
Price target
$7.00

Price

Company profile

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharm...

Show more

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Industry
Biotechnology
Sector
Healthcare
Phone
844 967 2633
Website
https://oramed.com
Address
1185 Avenue of the Americas, Third Floor, New York, United States

Latest news

Stocktwits

BioCEOsSukk Nov 12, 11:29 PM
$SCLX $SRNE IMO and NFA: After closely monitoring and researching Scilex moves since last September, I'm betting on number 3 below. Especially because on October 2, just days after Scilex's debt cliff with $ORMP was due (but has at least publicly remained unpaid), Oramed Execs exchanged underwater options for shares as per their previous shareholder meeting allowed. Something big is up IMO that will be very beneficial for shareholders of the tickers above, directly for Scilex and indirectly for the other two: "Connected Cap-Table Cleanup. Because Oramed holds a senior security interest and consent rights over Semnur's corporate actions, retiring the 12.5 million legal retainer shares on November 4, 2026—just days before Scilex's Q3 2026 10-Q deadline—strongly suggests Scilex, Semnur, and Oramed have been negotiating behind closed doors on: A debt settlement, asset-backed financing or third-party buyout."
3 replies
d_risk Nov 12, 10:32 PM
$ORMP - Oramed Pharmaceuticals Inc. - 10Q - Updated Risk Factors Oramed says Scilex missed its original note payment deadlines and warns it may be unable to recover the amounts owed. #riskfactors #secfilings 🟢 Added 🟠 Removed https://d-risk.ai/ORMP?filing=96X-ilUvgtLu_dKaHWcnH
0 replies
Dutchholdem Nov 3, 7:33 PM
$ORMP added big at 3.93. At some point this will fly again to at least 6. Could take some months though..
1 replies
Makingmillions192 Oct 31, 6:47 PM
$AQST $LEXX $ORMP This is exactly why we are seeing shorts covering.. they know there is massive binary risk holding shorts positions heading into this clinical human data readout… Peers like Entera (⁠$ENTX⁠) and Rani (⁠RANI⁠) commanded valuations 5x to 20x higher than $LEXX once they demonstrated human proof-of-concept for their delivery vehicles. Lexaria’s current setup—running Human Study #7 (⁠GLP-1-H26-7⁠) while maintaining active MTAs with PegBio and undisclosed pharmaceutical partners—mirrors the exact structural sequence Cyprumed and Entera used to force Big Pharma to move from exploratory MTAs to formal licensing transactions.
0 replies
Makingmillions192 Oct 31, 6:39 PM
$LEXX Peer Group Platform Valuations: Biotech platform companies with validated drug delivery IP (e.g., oral peptide formulation engines) typically trade at enterprise valuations between $40M and $80M prior to major commercial licensing. On a ~2.1M share float, a $40M–$60M valuation equates to roughly $16.00 – $24.00 per share. Relavent comps: $AQST - Trades at a significantly higher market capitalization (~$300M–$450M) $ORMP - Trades in the ~$70M–$100M market cap range $RANI - Trades in the $60-80M market cap range. Peers like Oramed or Aquestive re-rated once they proved human PK across larger patient groups. LEXX currently sits at the inflection point between exploratory animal/pilot data and registration-grade human comparative data. As Lexaria moves through Human Study #7 (⁠GLP-1-H26-7⁠), delivering strong unblinded head-to-head comparative data against Rybelsus®/Wegovy® without SNAC would align its platform value closer to the $40M–$80M peer benchmark.
0 replies
Rxskillz Oct 14, 4:21 PM
$ORMP good stock
0 replies
shimblum Oct 7, 9:57 PM
$ORMP explain the math to me. This company owns 20% of $DRTS
1 replies
Tazbro Sep 17, 12:33 PM
Selling this POS today for a loss. Five years waiting is enough.$ORMP
2 replies